A Telehealth-supported, Integrated care with CHWs, and MEhydration-access (TIME) Program for Diabetes Improves HbA1c: a Randomized Clinical Trial

Elizabeth M. Vaughan, DO, MPH1, David J. Hyman, MD, MPH1, Aanand D. Naik, MD1,2,3,4, Susan L. Samson, MD, PhD5, Javad Razjouyan, PhD2,3, and John P. Foreyt, PhD1

1Division of General Internal Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; 2Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E DeBakey VA Medical Center, Houston, TX, USA; 3Division of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; 4Division of Geriatrics and Palliative Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA; 5Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, USA.

BACKGROUND: Many individuals with diabetes live in low- or middle-income settings. Glycemic control is challenging, particularly in resource-limited areas that face numerous healthcare barriers.

OBJECTIVE: To compare HbA1c outcomes for individuals randomized to TIME, a Telehealth-supported, Integrated care with CHWs (Community Health Workers), and MEhydration-access program (intervention) versus usual care (wait-list control).

DESIGN: Randomized clinical trial.

PARTICIPANTS: Low-income Latino(a) adults with type 2 diabetes.

INTERVENTIONS: TIME consisted of (1) CHW-participant telehealth communication via mobile health (mHealth) for 12 months, (2) CHW-led monthly group visits for 6 months, and (3) weekly CHW-physician diabetes training and support via telehealth (video conferencing).

MAIN MEASURES: Investigators compared TIME versus control participant baseline to month 6 changes of HbA1c (primary outcome), blood pressure, body mass index (BMI), weight, and adherence to seven American Diabetes Association (ADA) standards of care. CHW assistance in identifying barriers to healthcare in the intervention group were measured at the end of mHealth communication (12 months).

KEY RESULTS: A total of 89 individuals participated. TIME individuals compared to control participants had significant HbA1c decreases (9.02 to 7.59% (−1.43%) vs. 8.71 to 8.26% (−0.45%), respectively, p = 0.002), blood pressure changes (systolic: −6.89 mmHg vs. 0.03 mmHg, p = 0.023; diastolic: −3.36 mmHg vs. 0.2 mmHg, respectively, p = 0.046), and ADA guideline adherence (p < 0.001) from baseline to month 6. At month 6, more TIME than control participants achieved >0.50% HbA1c reductions (88.57% vs. 43.75%, p < 0.001). BMI and weight changes were not significant between groups. Many (54.6%) TIME participants experienced ≥1 barrier to care, whereas 91.7% had medication issues. CHWs identified the majority (87.5%) of barriers.

CONCLUSIONS: TIME participants resulted in improved outcomes including HbA1c. CHWs are uniquely positioned to identify barriers to care particularly related to medications that may have gone unrecognized otherwise. Larger trials are needed to determine the scalability and sustainability of the intervention.

CLINICAL TRIAL: NCT03394456, accessed at https://clinicaltrials.gov/ct2/show/NCT03394456

KEY WORDS: diabetes; medication; low-income; group visits or shared medical appointments; community health worker; obesity.

J Gen Intern Med 36(2):455–63
DOI: 10.1007/s11606-020-06017-4
© The Author(s) 2020

INTRODUCTION

Eighty percent of individuals with diabetes live in low- or middle-income countries.1 In high-income countries, most (69%) of those suffering from diabetes are low- or middle-income.2 Resource-limited and minority populations have a greater prevalence of diabetes and more disease-related complications.1 Strategies to improve glycemic control are complicated by poverty, limited literacy, and access to medications and healthcare.3, 4 These severe disparities highlight the need for innovative changes.

One strategy to improve care in resource-limited settings is community health workers (CHWs). These individuals have been instrumental in improving patient outcomes for a variety of diseases and conditions including diabetes.5–8 Our recent study showed that CHWs successfully led diabetes group visits.6 Group visits or shared medical appointments are a...
cost-effective intervention, comprising of education, integrated primary care (e.g., medication reconciliation), and goal development. Most group visits are led by physicians or other health professionals, and, though bilingual providers add value in relating to the patient population, they are in short supply. Integrating CHWs into group visits has showed value in overcoming cultural and language barriers.

However, there have been major concerns related to inadequate CHW training and support. This has led to increased global interest in telehealth mechanisms including mobile health (mHealth), particularly as they relate to supporting CHWs by assisting with diagnostics, enhancing communication, and professional development, and, thereby, improving patient care. A study of 72 African American individuals revealed that CHW-participant mHealth collaboration improved participant diabetes self-management skills and provided support by connecting CHWs to the healthcare team. A systematic review and meta-analysis illustrated numerous benefits of CHW-participant mHealth interaction including appointment reminders and reporting from peripheral sites.

Though prior studies have demonstrated the effectiveness of CHWs and mHealth, their combination has not been evaluated. To evaluate this combined strategy in a clinical trial, investigators compared individuals with type 2 diabetes randomized to the program TIME (Telehealth-supported, Integrated care with CHWs, and MEdication-access) (intervention) versus usual care in the clinic (control). TIME consisted of CHW-participant mHealth communication, CHW-led diabetes group visits, and CHW-physician diabetes training and support via telehealth (video conferencing). Investigators evaluated clinical outcomes (i.e., HbA1c (primary), adherence to American Diabetes Association (ADA) standards of care) and CHW assistance in identifying barriers to healthcare. The overarching hypothesis was improved glycemic control of TIME compared to control participants.

**METHODS**

**Study Design and Setting**

This was a randomized, wait-list clinical trial conducted at a nonprofit clinic in Houston, Texas. Clinic eligibility included uninsured individuals earning ≤250% of the federal poverty level. The Institutional Review Board at Baylor College of Medicine approved the study. Written consent and signed group visit confidentiality forms were obtained from study participants.

**Identification, Recruitment, and Retention of Participants**

We recruited two cohorts 6 months apart. Eligible participants were adults (≥18 years) with type 2 diabetes (HbA1c ≥ 6.5%), self-identified as Latino(a), and Spanish-speaking. Individuals were excluded if they were pregnant, had an event that would alter HbA1c levels (e.g., recent blood transfusion), or did not attend at least one group visit. Methods to identify potential participants were through the clinic database (primary), clinic referrals, or word of mouth. The clinic database filtered for Latino(a)/Hispanic with diabetes (ICD-10 E11:9, E11:X). Study staff contacted eligible individuals by phone to explain the study and interested individuals were invited to an orientation. At orientation, investigators obtained baseline clinical and survey data, signed written consent, and randomized participants to TIME (intervention) or usual care (wait-list control) using an automatic number generator to achieve block randomization. A physician completed a secondary chart review to confirm eligibility.

To address the issue of participant retention in low-income settings, TIME included several strategies including establishing an efficient tracking system, CHW training to identify participant barriers, and room setup with intentional socialization periods arranged to promote a welcoming environment. Meals, childcare, in-class laboratory, and medication refills also were provided.

**Clinical Intervention Program**

TIME consisted of CHW-participant mHealth communication, CHW-led diabetes group visits, and CHW-physician diabetes training and support via telehealth. Usual care in the clinic included diabetes management with physicians (quarterly) and clinical pharmacists (monthly) in addition to routinely offered nutrition classes. To allow wait-list control individuals the opportunity to receive TIME, they were offered the intervention months 7–12. After receiving the group visits, participants returned to usual care. Month 6 HbA1c, blood pressure, weight, and survey data were gathered for the wait-list control group prior to them receiving the intervention. Attrition was defined as study staff inability to contact a participant by month 6.

**Community Health Workers.** CHWs (n = 6) were self-identified as Latino(a), fluent in Spanish, and maintained their state of Texas CHW certification (e.g., initial: 160-h certification course; renewal: 20-h continuing education biennially).

**Telehealth-support.** In our feasibility study, CHWs received quarterly, in-person training while in this investigation, they attended weekly video conferencing (ZOOM) meetings, which has been published elsewhere. In summary, a study physician met with CHWs for weekly training that paralleled the monthly group visit topics (30 min) and support (30 min) to address questions or concerns. This telehealth venue was well-accepted and significantly improved CHWs’ diabetes knowledge (p < 0.001).

A second telehealth support mechanism for CHWs and participants was mHealth. Each CHW was assigned 3–4 participants of whom they contacted weekly (months 1–6) or bimonthly (months 7–12) (call or text pending participant preference) to inquire about glucose control, medication adherence, and questions or concerns. CHWs taught their
participants how to use a secure, encrypted app (OhMD) for communication. Control participants followed the same pattern but it was delayed 6 months. They did not have any CHW contact while in usual care (months 1–6).

**Integrated care with CHWs.** We utilized our feasibility study for the group visit structure and curriculum (Table 1). Briefly, group visits were in Spanish, met monthly for 6 months on Saturdays from 9A-12P, and had the following format: vital signs, large group education, three small groups (n = 30 min/section), and a healthy meal. The three small groups addressed medical, social, and behavioral barriers to care. The large group topics focused on diabetes self-management and standards of care. Participants briefly met with a bilingual study physician individually for medication management. CHWs led the large group and social and behavioral small groups. Materials were available in English and in Spanish.

**MEDication-access.** To address challenges of adherence in low-income settings, a study physician prescribed medications offered at low costs: metformin, glimepiride, and pioglitazone. The latter two were chosen as they are associated with fewer adverse events than similar drugs from the same class.

### Study Outcomes

**Clinical.** The primary study outcome was glycemic control as measured by baseline to month 6 change of HbA1c. To evaluate individuals who maintained or achieved target (e.g., <7.0%) by month 6 and assess the number who achieved clinically meaningful decreases in HbA1c (≥0.5%) investigators also conducted a sub-analysis named responders, defined as meeting either or both markers. Other clinical outcomes were blood pressure, weight, and BMI, of which investigators obtained at baseline (orientation) and 6 months (month 6 group visits). Baseline to month 6 adherence to seven ADA standard of care markers were collected through chart review at the following timepoints: baseline/month 6 (appropriately dosed statin, B12 screening), baseline/month 6 and 1 year prior to each timepoint (annual screenings: retinal, comprehensive foot exam, microalbuminuria, influenza vaccination), and baseline/month 6 and time prior to each timepoint as dictated per current recommendations (pneumococcal vaccination).

Clinical outcomes were measured after the completion of the diabetes group visits rather than at the end of CHW-participant contact (12 months) due to introduction of multiple variables upon return to clinic including potential changes of providers, eligibility, and clinics. Month 6 was defined as 24 weeks after orientation ±4 weeks. To reduce bias toward the intervention group who may have had more frequent checks, account for potential time variations between study arms, and collect data of participants not present at group visits, a study physician conducted a secondary chart review for all participants and recorded the lowest month 6 clinical value for HbA1c, blood pressure, and weight. Study team technique for obtaining clinical measures reflected those of the clinic (e.g., recheck blood pressure in both arms after 15 min for levels ≥140/90). At baseline and month 6, participants who completed study data were entered to win a $100 grocery gift card.

**Barriers to Care.** Other outcomes included barriers to care and survey data (i.e., participant satisfaction, mental relaxation). Barriers to care data were collected for 12 months, obtained from the CHW-participant calling logs and chart review, and grouped into three categories: obtaining medications, appointment access, and clinic eligibility.

**Survey Data.** Survey data were gathered during group visits at month 6. If participants were not present, CHWs called them to conduct the survey. One survey contained 11 questions (participant satisfaction, quality of life (#1–7); open-ended comments (#8–11)) and utilized our feasibility study survey as a template (Appendix). Another survey, Use of Mental Stress Management/Relaxation Techniques, evaluated open-ended type and weekly quantity of relaxation participants experienced.

### Statistical Analyses

Investigators derived the sample size calculation from prior, high-quality group care diabetes studies that evaluated change of HbA1c as a primary outcome. Investigators used the Morris equation to calculate an estimated effect size (d) based on the mean pre-post change in the intervention arm minus the mean pre-post change in the control group, divided by the pooled pre-test standard deviation. Using mean HbA1c data from Sadur et al., intervention (pre: 9.48% (SD ± 1.9)/post: 8.18% (SD ± 0.9)) and control (pre: 9.55% (SD ± 1.9)/
post: 9.33 (SD ± 0.9)), investigators generated an estimated effect size dppe2 of −0.57. Our targeted sample size and power estimates were calculated using G*Power 3.129. Based on these data, investigators determined that a total sample size of 78 at the end of the trial was needed, assuming nominal values for the type I and II error rates (i.e., 5% and 20%, respectively, two-tailed) to provide sufficient power to detect a clinically significant HbA1c change. Assuming a 15% 6-month attrition rate for this population, a total sample size of \( N = 88–90 \) was needed for the primary study endpoint. Gpower, \( F \) test, and ANOVA repeated measures between factors used alpha < 0.05 and power = 0.8.

Continuous variables were assessed for normality and investigators utilized nonparametric tests for nonnormally distributed variables. Investigators used sequential regression and multiple imputation using chained equations (MICE) to handle incomplete data. Growth percentile approach to identify and remove outlier cases from the analysis, and generalized estimating equations for dichotomized repeated measures (i.e., ADA standards of care). Linear mixed models were used to evaluate the treatment effect on HbA1c, blood pressure, BMI, and weight change from baseline to month 6. Barriers to care were summed and recorded as percentile. Survey data were evaluated by gathering an item mean score. Investigators defined acceptability as high (3.5–4/4 or 8–10/10), moderate (2–3.4/4 or 4–7/10), and low (1–1.9/4 or 1–3/10) and totalled the items to create an overall score. If an item was omitted from a survey, the variable was excluded from analysis.

**RESULTS**

The CONSORT diagram (Fig. 1) demonstrates the combined flow of cohorts 1 and 2 from database extraction to study entry. Study staff called 692 (cohort 1: \( n = 352 \)) individuals. There were more females in the database (55.3%) and males had a higher (79.5%) no-show rate at orientation. A total of 89 total participants (intervention = 44) entered the study. Participant demographics are outlined in Table 2. There were no significant differences between groups in age, sex, work history, HbA1c, cholesterol, blood pressure, BMI, or weight. Most participants worked in domestic (\( n = 38 \)) or maintenance/construction (\( n = 22 \)) employment.

There was a slight (61.4%) preference for phone calls versus text message for CHW-participant communication. CHWs were usually successful contacting participants (median 85.0%, range 59.1%–100%), and most (83.3%) utilized both phone and text modalities. Group visit attendance averaged 66.7% (84.1% ≥50% show). Study attrition was 6.7% (\( n = 4 \) intervention, \( n = 2 \) control).

**Clinical Outcomes**

Figures 2 and 3 and Table 3 illustrate the subsequent clinical outcomes. Between-group comparisons showed that TIME compared to control participants had significant HbA1c baseline to month 6 changes (all: −1.43% vs. −0.45%, respectively, \( p = 0.002 \); uncontrolled: −1.93% vs. −0.62%, respectively, \( p = 0.007 \)), more responders (\( p = 0.015 \), OR = 2.33; 95% CI 1.21, 9.14), and a greater number who achieved ≥0.5% HbA1c reductions (88.57% vs. 43.75%, respectively; \( p < 0.001 \)). Though not significant, fewer TIME participants started at target HbA1c yet groups ended with similar numbers (\( p = 0.143 \)).

Within-group comparisons also revealed substantially greater effect sizes related to HbA1c improvements in TIME (\( p < 0.001 \), \( d = 0.79 \)) but not the control arm (\( p = 0.356 \), \( d = 0.20 \)). TIME compared to control participants resulted in greater systolic (\( p = 0.023 \)) and diastolic (\( p = 0.046 \)) blood pressure improvements and more achieving the seven guideline concordance measures (\( p < 0.001 \)). There were no significant differences in BMI or weight changes between groups. TIME individuals compared to control participants with baseline HbA1c < 7% lost more weight, though not significant (\( p = 0.691 \)) (Table 3).

**Barriers to Care**

A total of 54.6% (\( n = 24 \)) of TIME participants reported ≥1 barrier to care, of which 62.5% (\( n = 15 \)) experienced ≥2. Of these individuals, most (91.7%) experienced barriers related to medications (36.4% incorrect amount/none given, 36.4% lost eligibility to high-cost medications, 27.2% both) and some regarding clinic eligibility (16.7%) and appointment access (8.3%). The majority (87.5%) of these barriers were identified by CHW-participant interaction and the remaining by a study physician.

**Survey Data**

TIME participants recorded high satisfaction levels (3.8/4.0 ± 0.5). Most agreed that the program met their needs (3.8/4.0 ± 0.4), CHW-participant interaction was beneficial (9/10 ± 0.7), their health was better (9.7/10 ± 0.7), and they would come in the future and recommend the class (3.8/4.0 ± 0.5, 9/10 ± 0.4; respectively). TIME participants liked the education, individualized attention, staff, and suggested more than 6 months duration. The most common strategies for mental relaxation (mean two times/week) included exercise (28.2%), spirituality and rest (23.1% each), music (10.3%), and socialization (5.1%).

**DISCUSSION**

Diabetes is an epidemic that continues to increase, requiring innovative measures to prevent further burden to vulnerable populations. This study validated that participants in TIME achieved superior glycemic control, blood pressure, and ADA guideline adherence compared to control individuals. Rationale for these findings are an integrated, multifaceted program including the combination of mHealth and CHWs, which is a novel approach to care with promising results that show efficacy.
Compared to our feasibility study, this investigation resulted in superior glycemic and blood pressure outcomes. Overall, diabetes group visits and CHW interventions have shown effective HbA1c reductions (−0.46%, −0.71%, respectively) but less than those of the current study. This investigation transitioned from quarterly, in-person CHW training in our feasibility study to weekly, telehealth support. Also, this study strongly emphasized low-cost medications and combined CHWs and mHealth, which to our knowledge has not been published before in diabetes clinical trials. These factors likely contributed to the stronger findings from this study compared to our feasibility study and other investigations.

Telehealth (mHealth, video conferencing) was an important part of TIME. mHealth improved communication and connected CHWs and participants to the healthcare system, whereas video conferencing enhanced consistent training and support. These modalities likely greatly enhanced patient outcomes by assisting in high (87.5%) CHW ability to identify barriers to care, low attrition, physician communication, and,
thereby, improved glycemic control. These findings are consistent with a large body of literature that has shown improved support and communication associated with telehealth. Notably, the most common barrier to care related to medications and, therefore, the emphasis on low-cost hypoglycemic agents was critical. A study physician prescribed and maximized the most affordable ($4–$6/month) oral medications available at major pharmaceutical retailers and high-cost agents including insulin were initiated when inexpensive options had been exhausted. Participants taking high-cost medications upon study entry were continued if they remained effective and accessible. CHWs facilitated medication access by alerting a study physician when participants experienced barriers. Prior studies have agreed upon the complexity of medication adherence, noting cost as a major contributor. While many individuals experienced medication access barriers, others oftentimes were nonadherent due to fear, forgetfulness, and misunderstanding. This is a complex topic where integrated diabetes care with group visits was important. For example, during the large groups, CHWs emphasized nonadherence issues and subsequent breakout sessions allowed opportunities to discuss individual concerns, address questions, and provide collaboration.

### Table 2 Baseline Demographics and Clinical Information by Study Arm (N=89; Intervention = 44)

| Variable                     | TIME (n=44), n (%) | Control (n=45), n (%) | p value |
|------------------------------|--------------------|-----------------------|---------|
| Sex (female)                 | 34 (77.27)         | 30 (66.67)            | 0.271   |
| Work                         | 0.075              |
| Domestic                     | 15 (34.09)         | 23 (51.11)            |         |
| Maintenance, construction    | 9 (20.46)          | 13 (28.89)            |         |
| Unemployed, unknown          | 9 (20.46)          | 6 (20.46)             |         |
| Food service                 | 5 (11.36)          | 2 (4.44)              |         |
| Other (retired, office)      | 6 (13.64)          | 1 (2.22)              |         |

### Variable

| TIME (n=44); mean (+ SD) | Control (n=45); mean (+ SD) | p value |
|--------------------------|-----------------------------|---------|
| Age (years)              | 55.99 (7.12)                | 53.86 (9.07) | 0.220 |
| Diabetes diagnosis (years)| 14.28 (9.09)                | 11.38 (8.56) | 0.110 |
| Hemoglobin A1c (%)       | 9.02 (1.98)                 | 8.71 (2.34)  | 0.503  |
| Uncontrolled*            | 9.78 (1.79)                 | 9.76 (2.06)  | 0.968  |
| Total cholesterol (mg/dL)| 180.66 (42.56)              | 182.47 (44.54) | 0.845 |
| HDL cholesterol (mg/dL)  | 48.02 (10.63)               | 47.84 (12.85) | 0.943  |
| LDL cholesterol (mg/dL)  | 99.35 (37.02)               | 101.84 (38.12) | 0.758 |
| Triglycerides (mg/dL)    | 170.02 (76.52)              | 196.91 (111.31) | 0.187 |
| Systolic blood pressure (mmHg)| 131.64 (16.22) | 130.73 (13.64) | 0.777 |
| Diastolic blood pressure (mmHg)| 76.41 (7.70)   | 75.80 (7.99)  | 0.715  |
| Body mass index (kg/m²)  | 32.59 (6.30)                | 34.56 (8.22)  | 0.208  |
| Weight (kg)              | 80.36 (20.20)               | 85.75 (22.85) | 0.242  |

*Included those who needed ≥ 0.5% HbA1c reduction to achieve target levels (baseline > 7.4% (> 7.9% if ≥ 65 years old))

Figure 2 Comparison of HbA1c baseline to month 6 changes by study arm (N=89; TIME (intervention) n = 44). There were significant differences between group change of HbA1c from baseline to month 6 (p = 0.002). Within group changes were only significant for TIME participants (intervention: p < 0.001 (Cohen’s d effect size (d) = 0.79), control: p = 0.356, d = 0.20). TIME Telehealth-supported, Integrated care with Community Health Workers, and MEdication-access (intervention).
mHealth communication provided further education, feedback, and reminders.

Investigators included individuals with baseline-controlled HbA1c levels for two major reasons. HbA1c variability disproportionately affects low-income populations,\textsuperscript{43, 44} and, therefore, controlled individuals may have had substantially different glycemic levels in recent months. HbA1c variability has severe consequences including cardiovascular events, microvascular complications, and all-cause mortality.\textsuperscript{43, 44} Additionally, though there are strong recommendations for diabetes prevention,\textsuperscript{3, 45} most programs exclude those who are controlled. Weight management is particularly important for these individuals;\textsuperscript{3} though not significant, TIME participants who were controlled at baseline lost more weight than the control arm (Table 3). This finding may have been significant with more participants in this subgroup.

Our study is limited by time and a moderate sample size that is majority female, although most diabetes group visit investigations are less than a year, have high attrition, and are minority male.\textsuperscript{6, 10–12} Results are also limited to Spanish-speaking individuals at a nonprofit clinic. Though multifaceted interventions limit deciphering the most efficacious variable, these strategies have been found valuable for the complicated nature of diabetes.\textsuperscript{46} Long-term analyses including the role of behavioral health are difficult to assess in 6 months. Prior investigators found short-term success but failed to demonstrate sustainability.\textsuperscript{47} In the current study, weight-neutral

### Table 3 Baseline to Month 6 Clinical Changes by Study Arm (N = 89; Intervention = 44)

| TIME (intervention) | Usual care (control) | p value* |
|---------------------|----------------------|----------|
| HbA1c (%)           |                      |          |
| Uncontrolled†       | 9.78 ± 1.79          | 9.76 ± 2.06 | 0.007      |
| All participants    | 9.02 ± 1.98          | 8.71 ± 2.34 | 0.002      |
| HbA1c target‡       | 6 (13.64)            | 12 (27.27) | 0.143      |
| HbA1c reduction > 0.5%† | n/a (0%)          | 14 (34.75) | < 0.001    |
| Blood pressure (mHg) |                      |          |
| Systolic            | 131.64 ± 16.22       | 130.73 ± 13.64 | 0.023      |
| Diastolic           | 76.41 ± 7.70         | 75.80 ± 7.99  | 0.046      |
| Body mass index (kg/m²) |              |          |
| All participants    | 32.59 ± 6.30         | 34.56 ± 8.22  | 0.684      |
| Controlled baseline HbA1c | 32.84 ± 5.43 | 34.85 ± 7.22  | 0.691      |
| Weight (kg)         |                      |          |
| All participants    | 80.36 ± 20.20        | 85.75 ± 22.85 | 0.823      |
| Controlled baseline HbA1c | 77.96 ± 13.52 | 81.74 ± 15.63 | 0.691      |
| Preventive care§    |                      |          |
| B12 screening       | 0 (0.0)              | 68.75 ± 22.85 | < 0.001    |
| Statin therapy      | 13 (52.37)           | 67.56 ± 22.85 | < 0.001    |
| Comprehensive foot exam | 43 (97.72)         | 9.00 (0.0)   | < 0.001    |
| Influenza vaccination | 0 (0.00)            | 0 (0.00)    | < 0.001    |
| Pneumococcal vaccination | 16 (36.36)      | 10 (22.22)   | < 0.001    |
| Retinal eye exam    | 2 (4.50)             | 7 (15.60)    | < 0.001    |
| Urine microalbumin  | 4 (9.10)             | 9 (20.00)    | < 0.001    |

*Reflects baseline to month 6 group comparisons except HbA1c reduction variable, which was month 6 group comparisons
†Included those who needed > 0.5% HbA1c reduction to achieve target levels (baseline > 7.4% (> 7.9% if > 65 years old))
‡Defined as HbA1c < 7.0% (< 7.5% if > 65 years old)
§Guideline adherence as per American Diabetes Association.\textsuperscript{3} Data were gathered by chart review at the following timepoints: baseline/month 6 (appropriately dosed statin; B12 screenings; baseline/month 6 and 1 year prior for each timepoint (annual screenings—retinal, foot, urine, influenza vaccination); baseline/month 6 and time prior as dictated per ADA guidelines (pneumococcal vaccination)\textsuperscript{3}
outcomes may also relate to the addition of hypoglycemic medications associated with weight gain. 48

Several areas of future directions are warranted. Further variable and cost analysis of TIME’s multifaceted approach to diabetes care using multiphase optimization strategies or step-wedge designs are needed. Outcome sustainability after participants re-enter clinic are also warranted; observations suggest no clinically significant HbA1c change at ≥12 months for TIME participants. However, individual HbA1c trends demonstrate minimal improvement and possibly significant deterioration, which may be medication access related. Future studies should address clinic-wide strategies for sustainable medication access in low-income settings.

CONCLUSIONS
This study demonstrates the integral role of CHWs in a multifaceted diabetes program. CHWs are uniquely positioned to recognize medication barriers that would likely have otherwise been unidentified. Telehealth played a key part in supporting the program for both CHWs and participants. To increase the likelihood of sustainability, longitudinal evaluations of TIME are needed to evaluate the ability to implement the program in multiple sites.

Acknowledgments: The authors are grateful to the community health workers who were essential to the study findings. They also thank the host clinic for their willingness to serve as a study site.

Corresponding Author: Elizabeth M. Vaughan, DO, MPH; Division of General Internal Medicine, Department of Medicine Baylor College of Medicine, Houston, TX, USA (e-mail: elizabeth.vaughan@bcm.edu).

Funding Information: This work was supported to Dr. Vaughan by the National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, Federal Award Identification Number DK11034. Additional support was provided to Drs. Naik and Jazouliyan by the Houston Veterans Affairs Health Services Research and Development Center for Innovations in Quality, Effectiveness, and Safety. CIN 13-413 at the Michael E. DeBakey VA Medical Center.

Compliance with Ethical Standards: The Institutional Review Board at Baylor College of Medicine approved the study. Written consent and signed group visit confidentiality forms were obtained from study participants.

Conflict of Interest: The authors declare that they do not have a conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES
1. International Diabetes Federation. International diabetes atlas 8th ed. Brussels, BE: International Diabetes Federation; 2017:1-29.
2. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States. Atlanta: CDC; 2017.
3. American Diabetes Association. Standards of medical care in diabetes 2019. Diabetes Care. 2019;42(Supplement 1):S1-S183.
4. Kleinsinger F. The Unmet Challenge of Medication Nonadherence. Permut J 2018;22:18-033.
5. Scott K, Beckham SW, Gross M, et al. What do we know about community-based health worker programs? A systematic review of existing reviews on community health workers. Hum Resour Health. 2018;16(1):39.
6. Vaughan EM, Johnston CA, Moreno JP, Cardenas VC, Foyet JP. Integrating CHWs as Part of the Team Leading Diabetes Group Visits: A Randomized Controlled Feasibility Study. Diabetes Educ. 2017;43(6).
7. World Health Organization. Community health workers: What do we know about them? Geneva: World Health Organization; 2007.
8. Palmas W, March D, Daryakj S, et al. Community Health Worker Interventions to Improve Glycemic Control in People with Diabetes: A Systematic Review and Meta-Analysis. J Gen Intern Med 2015;30(7):1004-1012.
9. Burke RE, O’Grady ET. Group visits hold great potential for improving diabetes care and outcomes, but best practices must be developed. Health Aff (Milwood) 2012;31(1):103-109.
10. Vaughan EM, Johnston CA, Arlinghaus KR, Hyman DJ, Foyet JP. A Narrative Review of Diabetes Group Visits in Low-Income and Under-Served Settings. Curr Diabetes Rev 2019;15(5):372-381.
11. Housden LM, Wong ST. Using Group Medical Visits With Those Who Have Diabetes: Examining the Evidence. Curr Diab Rep 2016;16(12):134.
12. Davis A, Sawyer DR, Vinci LM. The potential of group visits in diabetes care. Clin Diabetes 2008;26(2):58-62.
13. Fernandez A, Perez-Stable EJ. Doctor, habla espanol? Increasing the Supply and Quality of Language-Concordant Physicians for Spanish-Speaking Patients. J Gen Intern Med 2015;30(10):1394-1396.
14. Cherrington AL, Agne AA, Lampkin Y, et al. Diabetes Connect: Developing a Mobile Health Intervention to Link Diabetes Community Health Workers With Primary Care. J Ambul Care Manage 2015;38(4):333-342.
15. Vaughan EM, Naik AD, Lewis CM, Foyet JP, Samson SL, Hyman DJ. Telemedicine Training and Support for Community Health Workers: Improving Knowledge of Diabetes. Telemed J E Health. 2020;26(2):244-250. https://doi.org/10.1089/tmj.2018.0113.
16. Zweben A, Fucito LM, O’Malley SS. Effective Strategies for Maintaining Research Participation in Clinical Trials. Drug Inf J. 2009;43(4).
17. Elliott SA, Brown JS. What are we doing to waiting list controls? Behav Res Ther 2002;40(9):1047-1052.
18. Texas Department of State Health Services. CHW Certification Requirements. 2019. https://www.dshs.texas.gov/chw/CertRequire.aspx. Accessed 16 April 2020.
19. Zoom. Video Conferencing for Telehealth. 2019; https://zoom.us. Accessed 16 April 2020.
20. OhMD. The modern healthcare communication platform. 2019; https://www.ohmd.com. Accessed 16 April 2020.
21. Lorig K, Holman H, Sobel D, Laurent D, Gonzalez V, Minor M. Living a Healthy Life with Chronic Conditions, 4th Edition. Boulder: Bull Publishing Company; 2012.
22. Skaff MJ, Robinson JR, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2898-2934.
23. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507-520.
24. Iturga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy 2014;7:35-44.
25. Simo R, Rodriguez A, Caveda E. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Curr Drug Saf. 2010;5(3):234-244.
26. Basit A, Riaz M, Fawad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag 2012;8:463-472.
27. Hameed UA, Manzar D, Raza S, Shareef MY, Hussain ME. Resistance Training Leads to Clinically Meaningful Improvements in Control of Glycemia and Muscular Strength in Untrained Middle-aged Patients with type 2 Diabetes Mellitus. N Am J Med Sci 2012;4(8):336-343.
28. Self-Management Resource Center (Stanford University). Mental Stress Management/Relaxation. 2019; https://www.selfmanagementresource.com/docs/pdfs/English_-_relaxation.pdf. Accessed 16 April 2020.
29. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30(6):1374-1383.
30. Sadur CN, Moline N, Costa M, et al. Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes Care 1999;22(12):2011-2017.
31. Trento M, Passera P, Borgo E, et al. A 5-year randomized controlled study of learning, problem solving ability, and quality of life modifications in people with type 2 diabetes managed by group care. Diabetes Care 2004;27(3):670-675.
32. Morris SB. Estimating effect sizes from pretest-posttest-control group designs. Organ Res Methods 2008;11(2):364-386.
33. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39(2):175-191.
34. Karcykar CS, Frederich R, Ravichandran S. Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. Int J Clin Pract 2013;67(8):759-767.
35. Huque MJ, Carlin JB, Simpson JA, Lee KJ. A comparison of multiple imputation methods for missing data in longitudinal studies. BMC Med Res Methodol. 2018;18(1):168.
36. van Buuren S, Groothuis-Oudshorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45:1-68.
37. Yang S, Hutcheon JA. Identifying outliers and implausible values in growth trajectory data. Ann Epidemiol. 2016;26(1):77-80 e71-72.
38. Landerman LR, Mustillo SA, Land KC. MODELING REPEATED MEASURES OF DICHTOMOUS DATA: Testing Whether the Within-Person Trajectory of Change Varies Across Levels of Between-Person Factors. Soc Sci Res. 2011;40(3):1456-1464.
39. Boateng GO, Neltlands TB, Frongillo EA, Melgar-Quinonez HR, Young SL. Best Practices for Developing and Validating Scales for Health, Social, and Behavioral Research: A Primer. Front Public Health 2018;6:149.
40. Marcelino MS, Oliveira JAG, D’Agostino M, Ribeiro AL, Alkmim MBM, Novillo-Ortiz D. The Impact of mHealth Interventions: Systematic Review of Systematic Reviews. JMIR Mhealth Uhealth. 2018;6(1):e23.
41. Morales LS, Lara M, Kington RS, Valdez RO, Escarce JJ. Socioeconomic, Cultural, and Behavioral Factors Affecting Hispanic Health Outcomes. J Health Care Poor Underserved 2007;13(4):477-503.
42. Rubin RR, Peyrot M, Kruger DP, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ 2009;35(6):1014-1022.
43. Critchley JA, Carey IM, Harris T, DeWilde S, Cook DG. Variability in Glycated Hemoglobin and Risk of Poor Outcomes Among People With Type 2 Diabetes in a Large Primary Care Cohort Study. Diabetes Care 2019;42(12):2237-2246.
44. Li S, Nemeth I, Donnelly L, Hapca S, Zhou K, Pearson ER. Visit-to-Visit HbA1c Variability Is Associated With Cardiovascular Disease and Microvascular Complications in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes Care. 2019.
45. Diabetes Prevention Program Research Group. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
46. Hirsch IB, Goldberg HI, Ellsworth A, et al. A multifaceted intervention in support of diabetes treatment guidelines: a cont trial. Diabetes Res Clin Pract 2002;58(1):27-36.
47. Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of Obesity. Med Clin North Am 2018;102(1):183-197.
48. Cheng V, Kashyap SR. Weight considerations in pharmacotherapy for type 2 diabetes. J Obes 2011:2011.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.